Ethylene oxide (EO) sterilization is widely used for heat- and moisture-sensitive medical devices, but toxic residues of EO and its by-product ethylene chlorohydrin (ECH) can remain in the product after processing. Exhaustive extraction testing determines the maximum extractable residue content of a device, providing a worst-case estimate of patient exposure in accordance with ISO 10993-7 and GB/T 16886.7. This article explains the principle, sample types, analytical methods, acceptance limits, and practical applications of EO residual exhaustive extraction testing for medical devices.
Technical Overview
Ethylene oxide gas sterilization is a dominant sterilization modality for medical devices that cannot withstand steam or high-temperature processing, including polymer-based single-use devices, complex assemblies, and packaging systems. Because EO is a reactive alkylating agent with demonstrated genotoxic, carcinogenic, and irritant properties, and because it reacts with chloride and water to form the toxic by-products ethylene chlorohydrin (ECH) and ethylene glycol (EG), regulatory authorities worldwide require manufacturers to demonstrate that residuals have been reduced to tolerable levels before product release.
ISO 10993-7 (adopted in China as GB/T 16886.7 and in Europe as EN ISO 10993-7) establishes the biological evaluation framework for EO sterilization residuals. The standard defines two product extraction strategies for demonstrating compliance: simulated-use extraction, which reflects the clinical use scenario, and exhaustive extraction, also known as limit or maximum extraction, which recovers the total extractable residue content of the device. Exhaustive extraction provides a deliberately conservative, worst-case measure of patient exposure and is the approach most commonly requested by reviewers for regulatory submissions.
Principle of Exhaustive Extraction
Exhaustive extraction is performed by repeatedly extracting the same specimen with fresh extraction medium until the residue released into the final extraction fraction falls below a defined threshold, typically less than 10 percent of the amount recovered in the first extraction. The total extractable residue is calculated as the sum of all extraction fractions. Because this procedure drives the device toward complete depletion of available EO and ECH, the reported result represents the theoretical maximum dose a patient could receive, independent of how the device is actually used clinically.
Standards and Regulatory Basis
- ISO 10993-7:2008 — Biological evaluation of medical devices, Part 7: Ethylene oxide sterilization residuals (limits and test options)
- GB/T 16886.7-2015 — Chinese national adoption of ISO 10993-7 for domestic registration
- ISO 10993-12 — Sample preparation and reference materials for biological testing
- ISO 10993-17 — Toxicological risk assessment, used to establish tolerable intake values
- ISO 11135 series and GB 18279 series — Validation and routine control of EO sterilization processes, including aeration
- ISO 10993-18 — Chemical characterization of medical device materials, complementary to residual studies
Testing Samples
Exhaustive extraction testing applies to any device or component that has been exposed to EO sterilization. Polymers such as plasticized PVC, silicone elastomers, polyurethanes, and polyethylene are of particular concern because they absorb EO readily and release it slowly during aeration. Samples should be drawn from fully aerated production lots, ideally including units from worst-case positions within the sterilization load. Testing is typically performed on three to ten production units per lot, using the device in its final, packaged, and sterilized configuration.
Single-Use Devices with Limited or Prolonged Patient Contact
This category includes sterile syringes, hypodermic needles, intravenous infusion sets, blood transfusion sets, extension tubing, stopcocks, in-line filters, hemodialyzers, extracorporeal circuit tubing, membrane oxygenators, anesthesia breathing circuits, urinary catheters, wound dressings, surgical drapes, and gowns. These products represent the highest volume of EO-sterilized submissions and are frequently evaluated using exhaustive extraction to satisfy registration reviewers.
Implantable and Long-Term Contact Devices
Absorbable and non-absorbable sutures, hernia repair meshes, intrauterine devices, intraocular lenses, scleral buckles, ligating clips, tissue repair patches, and certain orthopedic polymer components fall under prolonged or long-term contact categories. Because patient exposure is extended, residue limits become more stringent and exhaustive extraction provides the conservative dataset needed for toxicological justification.
Fluid Path and Container Products
Intravenous solution containers, parenteral nutrition bags, irrigation bottles, and complete fluid delivery assemblies are tested to quantify residues that may migrate into infused or irrigated fluids administered to the patient.
Multi-Material and Complex Assemblies
Endoscope components, electronic sensors, battery-powered devices, catheter assemblies with bonded adhesives, and combination products with mixed materials benefit from exhaustive extraction because different polymers desorb EO at very different rates, and a total-extraction approach captures contributions from every component.
Materials, Components, and Packaging Development Studies
Material screening, evaluation of alternative polymers, packaging permeability studies, and aeration cycle optimization during sterilization process development all rely on exhaustive extraction data to compare EO uptake and desorption behavior quantitatively.
Testing Items
The regulated analytes for EO sterilization residuals are defined in ISO 10993-7 and GB/T 16886.7:
- Ethylene oxide (EO) — the primary sterilant residue, subject to the strictest limits
- Ethylene chlorohydrin (2-chloroethanol, ECH) — the principal toxic reaction by-product
- Ethylene glycol (EG) — optional analyte; generally not assigned a device limit due to comparatively low toxicity, but sometimes reported for information or risk assessment purposes
Acceptance Limits per ISO 10993-7
Limits are expressed as the total extractable amount deliverable to the patient per device, based on the duration of patient contact:
- Limited contact (24 hours or less): EO not more than 4 mg per device, ECH not more than 5 mg per device
- Prolonged contact (more than 24 hours up to 30 days): EO not more than 2 mg per device, ECH not more than 2 mg per device
- Long-term contact (more than 30 days): limits are expressed as time-averaged daily doses derived from the tolerable intake values and calculation formulas in the standard, such as an average EO daily dose not exceeding 0.1 mg over the exposure lifetime
Where multiple devices are used in a single procedure, the residues are summed across all devices and compared against the applicable limit. Alternatively, when measured values exceed the default limits, ISO 10993-7 permits a justified risk-benefit evaluation using toxicological equivalence principles.
Testing Methods
Testing is performed by accredited third-party laboratories or in-house analytical facilities using validated headspace gas chromatography procedures. The complete workflow comprises sample preparation, sequential exhaustive extraction, instrumental quantification, and evaluation against ISO 10993-7 acceptance criteria.
Sample Receipt and Preparation
Specimens are handled in a manner that prevents volatile EO loss: packaging is opened only immediately before testing, devices are not pre-heated, and cutting or subdivision of large devices is performed at room temperature with minimal mechanical work. The patient-contacting portions are identified, specimen masses and dimensions are recorded, and the relationship between tested specimens and the complete device is documented so that results can be scaled to a per-device basis.
Exhaustive Extraction Procedure
- The specimen is placed in a gas-tight headspace vial with a measured volume of extraction medium, typically water for aqueous-contacting devices or another validated solvent for hydrophobic matrices
- The sealed vial is equilibrated under controlled temperature, commonly at body temperature conditions such as 37 degrees Celsius, for a defined period with agitation to promote partitioning of residues into the medium
- The first extraction fraction is analyzed, the spent medium is replaced with fresh solvent, and the extraction is repeated on the same specimen
- Sequential extractions continue until the residue measured in the final fraction is less than 10 percent of the first fraction, demonstrating that the specimen is effectively depleted
- The total extractable residue is computed as the sum of all fractions, corrected for dilution volumes and converted to milligrams per device
Instrumental Determination
EO is quantified by static headspace gas chromatography with flame ionization detection (HS-GC-FID), the reference technique for this analyte owing to its volatility. Confirmation by gas chromatography-mass spectrometry (GC-MS) is applied where required. ECH, being far less volatile, is determined in the aqueous extract by GC-MS, GC-FID with an appropriate injection technique, or high-performance liquid chromatography following a validated procedure. Quantification relies on matrix-matched calibration curves prepared from certified reference standards, supported by procedural blanks, spiked recovery studies, and replicate analyses to verify accuracy, precision, and sensitivity. Detection limits are typically well below the milligram-level regulatory limits, allowing compliant products to be demonstrated with substantial margin.
Data Evaluation and Reporting
The test report documents the extraction medium, temperature, number of extraction fractions, evidence that the exhaustion criterion was met, analytical results for each fraction and the cumulative total, method detection and quantification limits, and the final comparison against the ISO 10993-7 limits applicable to the device contact-duration category. A clear pass or fail conclusion with per-device residue values supports downstream regulatory review and product release decisions.
Applications
- Regulatory registration dossiers submitted to authorities such as NMPA, FDA, and notified bodies under the EU MDR, where EO residual data are a standard biocompatibility requirement
- Sterilization process validation and aeration cycle optimization under ISO 11135, using extraction data to demonstrate that degassing reduces residuals to acceptable levels within a defined holding time
- Routine product release testing for established product lines as part of the quality management system
- Design change, material substitution, supplier change, and packaging modification evaluations that may alter EO absorption or desorption behavior
- Shelf-life and post-sterilization stability studies confirming that residues remain controlled throughout the labeled usable life
- Investigations of out-of-specification results and root-cause analysis supporting corrective and preventive action programs
FAQ
What is the difference between exhaustive extraction and simulated-use extraction?
Simulated-use extraction mimics the clinical use scenario, extracting the device under conditions such as fluid flow rates, contact times, and temperatures representative of actual patient exposure, and is appropriate for devices with well-defined fluid pathways. Exhaustive extraction deliberately extracts all available residue through repeated solvent contact until depletion, yielding the theoretical maximum content of EO and ECH in the device. Exhaustive extraction is the more conservative method and is generally preferred for implants, devices without defined fluid paths, and regulatory submissions requiring worst-case data.
When is exhaustive extraction testing required?
It is required when a device is sterilized with EO and compliance must be demonstrated under ISO 10993-7 or GB/T 16886.7, particularly for implantable and long-term contact devices, for small-bore or low-fluid-volume devices where simulated use cannot realistically release all residues, and whenever reviewers request worst-case residue data. It is also used during sterilization cycle development to quantify total residue burden before aeration parameters are finalized.
Which analytes are measured and against which limits?
EO and ECH are the regulated analytes. For devices with patient contact of 24 hours or less, the limits are 4 mg EO and 5 mg ECH per device; for contact from 24 hours to 30 days, the limits are 2 mg EO and 2 mg ECH per device; for contact exceeding 30 days, time-averaged daily dose limits are calculated according to the formulas and tolerable intake values given in the standard.
How are EO and ECH quantified in the laboratory?
EO is measured by static headspace gas chromatography with flame ionization detection, optionally confirmed by GC-MS. ECH is measured in the aqueous extraction medium by GC-MS, GC-FID, or HPLC using validated methods. All procedures are supported by certified reference standards, blanks, recovery studies, and calibration to ensure traceable, defensible results.
How many samples are needed and how long does testing take?
Typically three to ten sterile production units from a representative, fully aerated lot are required, depending on device size and the sampling plan justified in the test protocol. Once the method is established for a product family, the extraction sequence plus instrumental analysis and reporting is commonly completed within one to two weeks, while new or complex products may require additional method development time.
